Correlation Between Enorama Pharma and Stille AB

Can any of the company-specific risk be diversified away by investing in both Enorama Pharma and Stille AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enorama Pharma and Stille AB into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Enorama Pharma AB and Stille AB, you can compare the effects of market volatilities on Enorama Pharma and Stille AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enorama Pharma with a short position of Stille AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enorama Pharma and Stille AB.

Diversification Opportunities for Enorama Pharma and Stille AB

0.27

Correlation Coefficient

Enorama Pharma  Stille AB

Modest diversification

The 3 months correlation between Enorama and Stille is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding Enorama Pharma AB and Stille AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Stille AB and Enorama Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enorama Pharma AB are associated (or correlated) with Stille AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Stille AB has no effect on the direction of Enorama Pharma i.e., Enorama Pharma and Stille AB go up and down completely randomly.

Pair Corralation between Enorama Pharma and Stille AB

Assuming the 90 days trading horizon Enorama Pharma AB is expected to under-perform the Stille AB. In addition to that, Enorama Pharma is 2.17 times more volatile than Stille AB. It trades about -0.07 of its total potential returns per unit of risk. Stille AB is currently generating about -0.02 per unit of volatility. If you would invest  21,800  in Stille AB on September 12, 2024 and sell it today you would lose (1,000.00) from holding Stille AB or give up 4.59% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Enorama Pharma AB  vs.  Stille AB

Enorama Pharma AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Enorama Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Stille AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Stille AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Stille AB is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Enorama Pharma and Stille AB

The main advantage of trading using opposite Enorama Pharma and Stille AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enorama Pharma position performs unexpectedly, Stille AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stille AB will offset losses from the drop in Stille AB's long position.

The idea behind Enorama Pharma AB and Stille AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.